Expediting pediatric access to new antiseizure drugs is particularly compelling, because epileptic seizures are the most common serious neurological symptom in children. Analysis of antiepileptic drug (AED) efficacy outcomes of randomized controlled trials, conducted during the past 20 years in different populations and a broad range of study sites and countries, has shown considerable consistency for each drug between adult and pediatric populations. Historically, the majority of regulatory approvals for AEDs have been for seizure types and not for specific epilepsy syndromes. Available data, both anatomical and neurophysiological, support a similar pathophysiology of focal seizures in adults and young children, and suggest that by age 2 years the structural and physiological milieu upon which seizures develop is similar. Although the distribution of specific etiologies and epilepsy syndromes is different in children from in adults, this should not impact approvals of efficacy based on seizure type, because the pathophysiology of focal seizures and the drug responsiveness of these seizure types are quite similar. Safety and pharmacokinetics cannot be extrapolated from adults to children. The scientific rationale, clinical consensus, and published data support a future approach accepting efficacy data from adult trials and focusing exclusively on prospective pharmacokinetic, tolerability, and safety studies and long-term follow-up in children. Whereas tolerability studies can be compared easily in children and adults, safety studies require large numbers of patients followed for many years.
In disease states affecting both adults and children, drugs are often approved for adult use before formal trials in children are completed or even started. Although antiepileptic drugs (AEDs) approved for use in adults can be prescribed off-label for children, 1 this availability can hamper pediatric drug approval in at least two ways. First, it heightens parents' reservations about enrolling a child with inadequately controlled seizures in a clinical trial of a marketed drug if the child could be randomized to placebo and remain on existing therapy, with no changes, for several months. Second, it creates an operational disincentive to undertake the challenges of conducting double-blind, randomized, controlled efficacy trials in children with seizures. Years typically elapse between the time an AED is approved and marketed as adjunctive treatment for adults with focal seizures and the drug is approved for pediatric use.
When prescribing AEDs off-label to children, physicians must rely on clinical judgment and experience to justify the unapproved use. In the absence of specific pediatric labeling or other supporting data, such off-label prescribing becomes increasingly problematic due to issues with reimbursement and legal liability. In the absence of pediatric-specific labeling, prescribers lack critical information (e.g., dosing, tolerability/safety, age-specific monitoring) that can facilitate the appropriate and safe use of AEDs in this vulnerable population.
The case for expediting pediatric access to new AEDs is particularly compelling because epilepsy is the most common serious neurological disorder in children. For ethical and legal reasons, almost none of the AEDs approved for the management of focal (partial onset) seizures included children <12 years of age in the initial clinical development program; the drugs were therefore marketed for use in older adolescents and adults. Labeling for pediatric use was added once double-blind, randomized, well-controlled trials in children were completed.
To avoid unnecessary clinical studies and thereby expedite pediatric access to drugs, the U.S. Food and Drug Administration (FDA) has established rules for the extrapolation of efficacy data from adequate, well-controlled studies in adults to children. 2 Because focal seizures occur in both children and adults, efficacy data from adults can be successfully extrapolated to children if there is scientific consensus that disease progression and response to intervention can be shown to be similar in adults and children, as outlined in the FDA guidance document. 2 Because AEDs for focal seizures are not evaluated as disease-modifying drugs (i.e., not antiepileptogenic), the focus of an argument for adult-to-pediatric efficacy data extrapolation is based on the similarity of seizure pathophysiology and the similarity of the clinical response to AEDs in terms of seizure control. Historically, FDA approvals have been for seizure types and not for specific epilepsy syndromes. Similarly, AED approvals in adults are based on seizure types and not on etiology. Therefore, although the distribution of specific etiologies, [3] [4] [5] [6] as well as epilepsy syndromes, 7, 8 will be different in children than in adults, this should not impact upon approvals based on seizure type if the pathophysiology of focal seizures and the drug responsiveness of these seizure types are similar.
Efficacy Results in Trials in Adults and in Children with Focal Seizures
As an alternative to placebo-controlled trials of AEDs in children, efficacy data extrapolated from adult AED clinical trials may be able to predict efficacy in children. 9 Such extrapolation has been used, with varying degrees of success, to secure new pediatric indication or labeling that has extended the pediatric age range in an array of drugs across different disorders. 9 The regulatory decision to derive pediatric labeling from adult data takes into account the disease and its natural history in adults and children, interactions between developmental changes and responses to therapy, experiences with drugs in the same class/indication, and the validity of efficacy endpoints in adults versus children. 9 Thus, extrapolation requires a reasonable degree of confidence that the disease and response to treatment are similar in adults and children.
To provide evidence of the similarity of focal seizures in adults and children and to evaluate the evidence for extrapolating AED efficacy data, treatment response in published randomized controlled trials in focal seizures were analyzed. 10 A total of 30 trials of gabapentin, lamotrigine, levetiracetam, oxcarbazepine, and topiramate as adjunctive therapy in focal seizures were analyzed: 24 trials in adults and 6 in children (2-18 years). Endpoints were a well-established measure of AED treatment effect, that is, percentage change from stable baseline seizure frequency measured as median percentage seizure reduction and/or proportion of patients with clinically significant response (≥50% reduction from baseline seizure frequency). Placebo-subtracted effect measures were calculated for each trial, standard
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• Extrapolating efficacy data for focal seizures provides a pragmatic response in phase with current health care needs of children with focal epilepsies errors were estimated, 95% confidence intervals (CIs) were calculated for the effect measures, and forest plots were created. 10 Median percentage seizure reductions in trials in children with focal seizures were generally comparable to seizure reductions in adults, recognizing that the reduction rates had considerable variability, ranging from 10.5% to 31.2% in children and from 7.0% to 58.6% in adults. CIs significantly exceeded 0 in six of six treatment groups in children and in 40 of 46 treatment groups in adults. Overall, the placebosubtracted effect measures for median percentage seizure reduction were consistent from trial to trial and were comparable between adult and pediatric studies for all five AEDs.
For 50% responder rates, placebo-subtracted effect measures vary widely in adults and children, but the results could be considered relatively comparable, ranging from 3.0% to 26.0% in children and from 2.0% to 43.0% in adults, Forest plots showed that CIs significantly exceeded 0 in five of eight treatment groups in children and 37 of 43 groups in adults. In the treatment groups in which the lower CI limit included 0, the mean difference and upper CI was within the range of "favors treatment."
The trials were conducted over a nearly 20-year span in different populations and a broad range of study sites and countries. This consistency, despite differences in, for example, duration of exposure and dosage (i.e., low, medium, high), provides evidence that AEDs effective in adults are also effective in children and therefore support extrapolation of efficacy data from adult studies as a possible alternative to conducting placebo-controlled efficacy trials in children. 10 However, a weakness of this analysis is that the number of studies in children, compared to adults, is limited. Nevertheless, the consistency of results in children and adults supports the conclusion that extrapolation of efficacy of AEDs in focal seizures from adults to children is valid.
After the analysis of those 30 trials was published, one AED (perampanel) subsequently received approval in adults and adolescents (age 12 and older) based on three randomized controlled trials, in which median seizure reduction ranged from 23% to 29% (4-12 mg) versus placebo median reduction of 13%, and responder rates ranged from 29% to 35% versus a placebo response of 19%.
11 Adolescents comprised about 10% of the overall study population in the perampanel controlled trials. A post hoc analysis found that perampanel reduced median seizure frequency in drug-resistant adolescents (age 12-17 years) by 34.8-35.6%, about twice the rate of placebo, with responder rates of 40.9-45.0% (vs. 22.2% with placebo). 12 In adolescents, efficacy was generally consistent with the overall results for the 8-and 12-mg groups, that is, median seizure reductions of 32.4-34.9% and responder rates of 37.3-40.8%. 13 The consistency of results between adults and adolescents in the perampanel trials adds further to the evidence supporting the extrapolation of adult efficacy data to children. 12 
Rationale for Pediatric Epilepsy
Academic Consortium for Extrapolation Position
In 1994, a workshop convened by the National Institute of Neurological Disorders and Stroke addressed in detail the extrapolation of adult efficacy data to children.
14 Twenty years later, clinical and basic data have further strengthened this viewpoint. In adequately powered clinical trials in children with focal seizures, AEDs that are effective in adults with focal seizures have also been found to be effective in children.
Because AEDs for focal seizures are not evaluated as disease-modifying drugs (i.e., not antiepileptogenic), the focus of an argument for adult-to-pediatric efficacy data extrapolation is based on the similarity of seizure pathophysiology and the similarity of the clinical response to AEDs in terms of seizure control.
Biological Evidence Supporting Extrapolation of AED Efficacy in Focal Seizures from Adults to Children (≥2 years)
A seizure can be conceptualized as occurring when there is an imbalance between excitation (E) and inhibition (I) in the brain. 15 The factors that alter the E/I balance can result from aberrations at many levels, from genes and cellular signaling cascades to widespread neuronal circuits. The hallmark of focal seizures on the electroencephalogram (EEG) are interictal spikes that physiologically are characterized by a prolonged paroxysmal discharge (the spike) followed by a period of hyperpolarization (slow wave). 16, 17 The paroxysmal depolarizing shift (PDS) is initiated by rapidly responding a-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) activation but is maintained by the longer-acting N-methyl-D-aspartate (NMDA) receptor. The post-PDS hyperpolarization temporarily stabilizes the neuron. If this post-PDS hyperpolarization fails, prolonged depolarization with recurrent action potentials occurs, resulting in ictal discharges. 18 The sustained depolarization appears to be synaptically mediated, 19 indicating that focal seizures can be mediated by an excess of excitation relative to inhibition.
Whereas the pathophysiological basis for focal seizures is similar in the immature and mature brain, 20 the driving forces contributing to seizure onset and propagation are dependent on the anatomical/structural and neurophysiological milieu on which seizures develop. For example, c-aminobutyric acid (GABA) during fetal and early life is depolarizing rather than hyperpolarizing. 21, 22 AEDs that enhance GABA could conceivably be proconvulsant rather than anticonvulsant. 23, 24 Likewise, anatomical differences between the immature and mature brain may affect AED efficacy. For example, in the immature brain there is an overabundance of asymmetrical synapses, which are typically excitatory synapses, compared to the mature brain. 25 To determine whether focal seizures are similar in children and adults, the Pediatric Epilepsy Academic Consortium for Extrapolation (PEACE) group compared the anatomical/ structural and neurophysiological milieu on which seizures may develop at comparable ages in rodents and humans, specially asking whether there are any significant anatomical or neurophysiological development events during childhood that could result in reduced efficacy to AEDs used for focal seizures in adults. In addition, we also examined rodent studies in which AEDs were administered to both immature and mature animals to determine whether AED efficacy was influenced by ontogenesis.
Anatomical/morphological evidence
Although rodent studies are valuable in delineating the timing of developmental events, extrapolation of developmental time points are estimates, because biology and maturation patterns differ between the species (e.g., in the rate of neurogenesis, differentiation, neurotransmission, and connectivity). 26, 27 To estimate equivalent human age, we relied on a model that integrates >1,000 empirically derived neural events to translate neurodevelopmental time across mammalian species, including humans and rats (http://www.-translatingtime.net). 28, 29 In regard to whole brain growth and myelination, a postnatal day (P) 38 rat would be equivalent to a 24-month-old child. However, not all structures mature at the same rate in rats and humans. For example, corpus callosum myelination is complete at P42 in the rat and at 6 months old in a child, whereas peak visual cortex synaptic density occurs at P30 in the rat and before birth in a child. Despite some variability in the trajectory of developmental changes in rats and humans, extrapolation across species allows one to predict whether interventional therapies are likely to have similar effects in the two species.
Although the brain continues to develop throughout childhood, particularly in regard to myelination, by the age of P38 in the rat and 2 years in the child all brain structures have formed and major growth has already occurred. By age 2 years, the human brain is >80% its maximum brain weight, axons have reached their targets 30, 31 and are myelinated, 32 the peak of neurogenesis 33, 34 and synaptogenesis has occurred, 35, 36 and the critical periods for formation of auditory and visual circuits has ended. 37, 38 By P21, rat dendrite and axonal arborization, and synaptic contacts are similar to adults. [39] [40] [41] [42] We thus consider that a P38 rat extrapolates reasonably well to a 2-year-old child when considering anatomical and morphological similarities.
Neurophysiological evidence
We next considered major physiological changes occurring during brain development and how such changes may impact response to AEDs. It is well recognized that children are at higher risk for seizures than adults. 3, 5, 43, 44 Studies from animal studies parallel clinical studies, demonstrating that the immature brain is more susceptible to seizures than the adult brain. [45] [46] [47] [48] Kindling, a process in which recurrent electrical stimulations that initially result in brief electrical discharges and mild behavioral changes but result progressively in more prolonged and intense electrical and behavioral seizures, occurs at all ages. Young animals kindle more rapidly than mature animals. 49 In addition, a shorter period of postictal refractoriness in young animals leads to a quick progression through early stages of kindling and results in rapid generalization of seizures. 50 Immature rats are more likely to develop seizures with hypoxia than mature rats. 51 Similarly, immature rats are quite susceptible to the chemoconvulsants, such as kainic acid, shortly after birth. 52 Whether heightened brain excitability during early brain development results in different efficacy of AEDs in the immature compared to the mature brain is an important question.
There are several reasons for this enhanced excitability in the immature brain, compared to the adult brain. Morphological differences in the size of neurons confer membrane properties that make the cells more excitable. Due to their small size, immature neurons have higher input resistances and longer action potential duration than mature neurons in both rabbits 53 and rats. 54 However, their cell properties reach adult values by 2-3 weeks.
In the adult, glutamate is the primary excitatory neurotransmitter, and GABA is the principal inhibitory transmitter. Synaptic transmission is mediated by glutamate that is released from the pyramidal neurons and depolarizes and excites the target neurons via ionotropic receptors NMDA, AMPA, and kainic acid. Although all glutamate subreceptors respond to glutamate, each subreceptor has individual characteristics. The AMPA receptor rapidly responds to glutamate with opening of the channel to allow Na + to enter the cell and depolarize the membrane. The NMDA channel has characteristics of both a ligand-activated and a voltage-sensitive channel. Ion flow through the channel is normally blocked by Mg 2+ . Only with depolarization of the membrane is Mg 2+ dislodged and Na + and Ca 2+ ions are able to cross the channel. The rise of intracellular Ca 2+ is essential for neurotransmitter release at the synapse. Activation of GABA A and GABA B results in hyperpolarization of the membrane and a reduction of excitability and action potential generation.
During development, these receptors are not functionally expressed simultaneously, but rather occur in a sequence of GABA A ? NMDA ? AMPA. 55 This sequence is important, as GABA provides the main excitatory drive to hippocampal neurons at early stages of postnatal development because of a high Cl À content in immature neurons. 22, 56 Opening of the Cl À channels with efflux of Cl À leads to depolarization of young neurons, rather than the hyperpolarization observed in adults. Consequently, in the immature brain, GABA A responses result in Cl À efflux, depolarization, and subsequent activation of voltage-dependent Na + and Ca 2+ channels. 57 The depolarization produced by GABA is sufficient to remove the voltage-dependent Mg 2+ block from NMDA channels, thereby inducing large Ca 2+ influx into immature neurons. Initially discovered in the hippocampus, this effect of GABA has now been described in all brain structures studied. 58 The depolarizing-to-hyperpolarizing shift is mediated by an active Na 59 However, after the first year, GABA is hyperpolarizing rather than depolarizing. Taken together, these findings suggest that GABA switches from depolarizing to hyperpolarizing very early in humans.
In addition, in the immature brain there is enhanced excitation due to an overabundance of NMDA and AMPA receptors. [60] [61] [62] Glutamatergic NMDA receptors are heteromeric complexes composed of an obligatory NR1 subunit and modulatory NR2A-D subunits that exhibit distinct physiological and pharmacological properties. In the infant, there is an excess of fetal-type NMDA receptors (NR2B/D) that exhibit longer channel opening than the mature variant (NR2A). 63 By P23-25 in the rodent and by age 2 years in the human, NMDA receptors have the same subunit configuration as in adults. The AMPA receptor subtype is also heteromeric in structure and is comprised of a combination of the GluR1, GluR2, GluR3, and GluR4 subunits, and is permeable to Ca 2+ when GluR2 is lacking. 64 Ca 2+ influx through GluR2-lacking AMPA receptors represents a major mechanism implicated in the normal processes of synaptic plasticity, learning, and memory. 65 By P14 in the rodent and year 2 in the human, GluR2-lacking pyramidal neurons reach levels seen in adults. 66 Because many of the AEDs used to treat focal seizures target ion channels, it is important to determine whether the ion channels are structurally and functionally similar in the immature and mature brain. The human Na + channels, voltage-gated ion channels crucial for the generation and propagation of action potentials, are heteromeric complexes consisting of a larger a subunit and two smaller b subunits. There are four main voltage-gated Na + channels expressed in the central nervous system: Nav1.1, encoded by the gene SCN1A, along with Nav1.2, Nav1.3, and Nav1.6, encoded by the genes SCN2A, SCN3A, and SCN8A, respectively. The expression patterns of these channels change during development. Nav1.1 and Nav1.6 expression increases during development, 67, 68 with Nav1.1 expression reaching adult levels over the first month in rodents. 67, 68 Interestingly, Nav1.2 and Nav1.3 expression appears to decline during postnatal development, 68, 69 However, from one brain region to another, Nav1.2 expression changes may vary. 70 Overall, these reports suggest there is a relative switch in the expression of these voltage-gated sodium channels in the brain that occurs gradually during development, over the first 4 weeks of life in rodents. [68] [69] [70] In humans, Nav1.1 expression in the hippocampus and cortex also increases during early development, peaking around 7-9 months of age. 71 Thus, by age 2 years children have a mature pattern of Na + channels. Neuronal voltage-gated Ca 2+ channels, which generate rapid, transient intracellular Ca 2+ in response to membrane depolarization, are present and fully functional at birth in rats 72, 73 and in humans. 74, 75 K + ions also are functional in rats and humans at birth. 76 As demonstrated in Fig. 1 , major anatomical and physiological events that would influence seizure onset and propagation are complete by P38 in rats and age 2 years in children. Thus, in regard to the anatomical, structural, and electrophysiology development profile in the developing brain, there is compelling evidence that by age P38 in the rat and age 2 years in the child the brain is similar to the young adult brain and there is no compelling reason to conclude response to AEDs for focal seizures would be different in children and adults.
Response to AEDs during ontogenesis
Another step in determining whether extrapolation of efficacy of AEDs in adults with focal seizures extends to children is to examine rodent studies in which efficacy of AEDs in seizure models are assessed during ontogeny. In animal models, pharmacological agents that result in focal seizures in adult rodents likewise cause focal seizures in immature rats, [77] [78] [79] [80] again supporting the concept that the pathophysiological underpinnings of focal seizures are similar in the adult and immature brain.
The response to AEDs in developing rats in a variety of seizure models has shown that efficacy in immature rats (<P40) is similar in adult rats (>P60). AEDs studied have included phenobarbital and primidone, 78, 81, 82 carbamazepine and oxcarbazepine, 83 98, 99 An important caveat is that many of the studies used a model of generalized seizures, such as pentylenetetrazol, as compared to focal seizure models. Nevertheless, although there are some age-related effects on seizure semiology, in none of the studies did the investigators find that an AED either exacerbated seizures in immature rats or showed less efficacy in immature rats.
Clinical Evidence Supporting Extrapolation of AED Efficacy in Focal Seizures from Adults to
Children (≥2 years)
The PEACE group next evaluated clinical evidence supporting extrapolation of AED efficacy in focal seizures from adults to children by comparing EEG features in the immature and mature brain. The EEG is a dynamic measure of brain maturity, 100, 101 with certain EEG patterns appearing and disappearing as a function of age. As such, the EEG is a surrogate measure of brain maturation.
Neurophysiological evidence-EEG
EEG is one method to explore the network dynamics underlying brain activity. 100 By age 2 years, the EEG is quite similar to a young adult, with a well-developed, reactive alpha rhythm of 7-8 Hz, distinct centroparietal rhythms, and well-formed frontally dominant fast activity (Fig. 2 ). Even earlier, by age 6-8 months, there is a wellformed, symmetric, and synchronous sleep architecture identical to that found in adults. In a study of sleep spindles in children from 2-5 years of age, it was found that spindle duration, amplitude, and power increased with age, whereas mean spindle frequency decreased. 102 Importantly, there was no change in spindle density with increasing age (Fig. 3) . Although sleep EEG coherence increases across development in a region-and frequencyspecific manner, the changes after age 2 years are minimal. 103 In short, the pediatric EEG at age 2 years has the principle components of the adult, indicating that there are comparable neural networks that are essential for normal brain oscillations.
Electrophysiological evidence of clinical-behavioral evolution of focal seizures
Clinical manifestations of focal seizures vary as a function of age. Over time, children acquire more elaborate features; by early school age, many of the same characteristics seen in adolescents and adults are present in children with focal seizures. One study analyzed detailed ictal manifestations from video-EEG recordings of 123 patients with focal seizures and compared them to recordings in infants younger than 2 years, in preschool children (2-6 years), and in older children. 104 Statistically significant variations were seen in the frequency of aura, limb automatisms, dystonic posture, secondary generalization, and unresponsiveness across the three age groups, with all of these features becoming more common with increasing age. Conversely, the frequency of asymmetric clonus and symmetric tonic postures decreased with age. By preschool or early school age, differences between children and adults were far less significant, and childhood focal seizures appeared to take an adult form. 104, 105 Nordli et al. 104 also showed that the clinical neurophysiological correlate of focal seizures is constant across the age span. Even in the very young, focal seizures bear a close resemblance to those in adults, with sustained rhythmic patterns that evolve in frequency and spatial distribution over time. Additionally, no differences were noted in the frequency or other components of focal ictal discharges. There is a predilection for more posterior onsets in the very immature, which corresponds to the known posterior to anterior gradient of brain myelination, 106 ,107 but more anterior foci appear by early school age.
In summary, beyond the neonatal period, the electrographic features of focal seizures are quite similar across the age spectrum. Subtle clinical expressions have been noted in the immature brain, but focal seizures take on many mature characteristics by early school age. EEG and clinical data support the claim that focal seizures in children older than 2 years are strikingly similar to their adult counterparts.
Thus, after excluding children younger than 2 years and those with focal seizures associated with epileptic encephalopathies such as Lennox-Gastaut syndrome, the pathophysiology of focal seizures is similar in children and adults. These findings are in concordance with the analysis of published randomized controlled trials of AEDs in focal seizures. 10 Taken together, these findings support the 
Limitations of Extrapolation
There are risks of extrapolation of adult data to children. The number of comparable trials of AEDs in children and adults is small, limiting confidence in extrapolation of all AED efficacy data in adults to children. There are concerns that if efficacy is not rigorously tested in young children, age-related differences in efficacy may not be detected until the AEDs are widely used. Also, the pharmacokinetics (PK), pharmacodynamics (PD), and safety effects of AEDs may be age-related and young children may respond much differently to AEDs than adults. Whereas tolerability can be relatively easily compared in children and adults, safety studies determining serious adverse effects that are usually rare require large numbers of patients evaluated over long periods of time. Extrapolation of safety data from adults to children is therefore risky.
Regulatory Considerations for Extrapolation
In 2000, the International Conference on Harmonization (ICH) drafted a guideline that stated, "When a medicinal product is to be used in the pediatric population for the same indication(s) as those studied and approved in adults, the disease process is similar in adults and pediatric patients, and the outcome of therapy is likely to be comparable, extrapolation from adult efficacy data may be appropriate. In such cases, pharmacokinetic (PK) studies in all the age ranges of pediatric patients likely to receive the medicinal product, together with safety studies, may provide adequate information for use by allowing selection of pediatric doses that will produce blood levels similar to those observed in adults. If this approach is taken, adult PK data should be available to plan the pediatric studies." 108 Since adoption of that guideline, pediatric drug development has been enhanced by advancements in several areas of general adult drug development, without a parallel development of the harmonized guidance in these areas. A July 2014 addendum to address new scientific and technical advances in pediatric drug development added that extrapolation of data in pediatric drug development is an area "where technical and regulatory assessments and consensus is evolving" acknowledging that "there are differences in how regulatory authorities define extrapolation and consider limitations to the utilisation of extrapolated data." 109 Both the FDA and the European Medicines Agency (EMA) endorse the concept of extrapolation of efficacy from adult clinical trials to pediatric patients. EMA specifically endorses extrapolation for focal seizures, stating, "Focal epilepsies in children older than 4 years old have a Figure 2 . Alpha frequency as a function of age. Examples are shown of alpha rhythm in a 2-year-old and a 16-year-old (underlined). Epilepsia ILAE similar clinical expression to focal epilepsies in adolescents and adults. In refractory focal epilepsies, the results of efficacy trials performed in adults could to some extent be extrapolated to children provided the dose is established." 110 When the course of the disease or the outcome of therapy in children is expected to be similar to adults but the appropriate blood levels of pharmacotherapy are not clear, it may be possible to use PD to define the dose/concentration needed to achieve efficacy. Such PD studies could provide clinicians with confidence that achieving a given drug exposure should result in the desired therapeutic outcome. Thus, a PK/PD approach combined with safety and other relevant studies could avoid the need for clinical efficacy studies.
Current FDA policy is that if "the course of disease and the effect of the drug are sufficiently similar in adults and pediatric patients, effectiveness in the pediatric population may be extrapolated from adult data." 2 The FDA Pediatric Study Decision Tree further requires that, to consider extrapolation of efficacy, it should be reasonable to assume similarity of concentration-response relationships between adults and children. 2 If these conditions are fulfilled, efficacy may be extrapolated without repeating clinical trials for the same indication in children. PK studies to achieve plasma concentrations in children similar to those in adults and safety/tolerability trials to characterize adverse effects in a pediatric population are also necessary. The analysis by Pellock et al. 10 of AEDs with published trials in focal seizures showed clinical response relationships in adults and children were similar on the basis of comparable PD effect sizes between these populations; information on similarity of concentration-response relationships are not available in the published literature.
One option for meeting the FDA requirement for extrapolation might be to derive concentration-response relationships for all AEDs from clinical trials in adults and children. If there is insufficient data to derive concentration-response relationships for all AEDs, a second option would be to demonstrate proof of principle with two or more AEDs (preferably with different mechanisms of action) for which concentration-response relationships can be compared. If the proof of principle is valid, it might be reasonable to expect that similar concentration-response relationships are present for other AEDs with comparable PD effect sizes between adults and children, but this should be confirmed. This approach combines the ICH guideline principles with the FDA requirements and would provide an alternative and Spindle density across age. Box plots are shown of sleep spindle density at age 2, 3, and 5 years for each electroencephalographic derivation (C3A2, C4A1). Upper and lower borders of box plots represent upper and lower quartiles, tails represent minimum and maximum scores, the vertical midline represents the median, and outliers are indicated by +. No differences across ages were seen. Reprinted with permission from McClain et al. 102 Examples are shown of sleep spindles in a 2-year-old and a 16-year-old (underlined). Epilepsia ILAE globally harmonized regulatory pathway for clinical development of AEDs in children.
This article was originally prepared and submitted to the FDA with the goal of harmonizing the regulatory pathway for extrapolation of efficacy across regulatory agencies. Thus, the age group of 4 years and older, as outlined in the EMA guidance document, was proposed as the pediatric age group where extrapolation may be considered appropriate and acceptable. The FDA revised regulatory policy in 2015 to accept extrapolation of efficacy based on the proposal. Because the scientific evidence presented in this article supports disease similarity to a younger age than previously proposed for regulatory consensus, extrapolation of efficacy to age 2 years and older would be scientifically valid and clinically appropriate.
Recommendation
Therefore, PEACE proposes that AEDs shown to be effective in adults with focal seizures also be considered effective in children ≥4 years of age. Our proposal applies only to epilepsies for which seizure types are restricted to focal (partial onset) seizures with or without secondary generalization. 111 We are not including generalized epilepsy syndromes (e.g., Lennox-Gastaut syndrome) or mixed generalized and focal disorders (e.g., Dravet syndrome). This proposal is also limited to efficacy. Safety, tolerability, PK, and other related issues cannot be extrapolated from adults to children; studies to address issues beyond efficacy will be needed. Carrying out such prospective PK and safety studies (not necessarily randomized studies) in children is both appropriate and not nearly as daunting a task as randomized placebo-controlled efficacy and safety studies. We have presented an argument that the scientific rationale, clinical consensus, and published data support this approach.
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